European Archives - Page 929 of 1056 - European Medical Journal

Continue
10 Jun 2016

New Data Demonstrates Sandoz’ Etanercept and Rituximab Biosimilar Candidates Bioequivalent to Originator Products

Holzkirchen, June 9 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies…
EMJ
9 Jun 2016

T Cell Protein Provides New Leads in Understanding Immune Response

AN INNOVATIVE new study has uncovered a protein that is fundamental to controlling immune responses, which could provide much needed clarification of…
EMJ
9 Jun 2016

New Insight into the Components of Pollen Proves Positive for Hay Fever Sufferers

NON-ALLERGENIC components of pollen do impact the body’s immune system, a recent study has uniquely revealed. The discovery could transform the future…
2 Jun 2016

Artificial Hip Joints and Obesity: Risk of Complications Rises with BMI but Benefits Predominate

Geneva, 2 June 2016 – Every tenth patient who receives an artificial hip joint in Europe is obese. This is a big challenge for orthopaedic surgery…
2 Jun 2016

Learning from Actual Practice: Registry Studies Promote Quality Treatment

Geneva, 1 June 2016 – What kinds of prosthetic joints are frequently used in a specific country? How durable are they and how often do they cause…
2 Jun 2016

Prevention Is the Key: EFORT Calls for Better Frameworks to Keep People Moving and Active

Geneva, 1 June 2016 – Keeping people active, mobile and pain-free throughout life, and the contribution orthopaedics can make in an ageing society are…
2 Jun 2016

Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis from Two Phase III Studies for Anamorelin in Cachectic Patients with Non-Small Cell Lung Cancer (NSCLC)

Lugano, Switzerland, June 1, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it will present…
2 Jun 2016

Janssen’s IMBRUVICA®▼(Ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia

Beerse/Belgium, 31 May, 2016 – Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved IMBRUVICA®…
2 Jun 2016

European Commission Approves TREVICTA®(Paliperidone Palmitate a 3-Monthly Injection), for Maintenance Treatment of Schizophrenia

BEERSE, BELGIUM, 31st May 2016 – Janssen-Cilag International NV announced today that the European Commission (EC) has approved the use of TREVICTA®…
31 May 2016

Children’s Digestive Health Across Europe in Crisis

Brussels, 31 May, 2016: A report investigating the current state of digestive health in children has revealed alarming trends in disease incidence and…